Saturday, April 10, 2021 6:34:26 PM
Does it dawn on you that every PR is proofread, reviewed, discussed, edited and perhaps modified by the board or management? In my opinion it is one or all of these, since they know that every time they do this, they are releasing the essence or intrinsic value of the stock as a whole. If the substance of the PR is not appealing to the eyes and ears of the investors, they should know that it could be a collection of ideas from the management. I think we should not second guess them...just my opinion.
Recent AUPH News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:31:08 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/13/2026 11:27:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:56:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:18 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:03:47 PM
- Aurinia Announces Management Transition • Business Wire • 03/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:06:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:02:50 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress • Business Wire • 02/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:08:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:05:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:04:33 PM
- Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 • Business Wire • 02/19/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:49:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 09:12:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 09:11:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2025 01:00:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/04/2025 11:06:12 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress • Business Wire • 11/04/2025 11:00:00 AM
- Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 • Business Wire • 11/03/2025 11:00:00 AM
